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Synovial sarcoma is a mesenchymal tissue cell tumor that
exhibits epithelial differentiation. Most frequently, it arises in
the extremities of adolescents and young adults (1), while a pri-
mary occurrence in the mediastinum is quite rare (2). Primary
mediastinal synovial sarcoma is a malignant tumor, able to
invade adjacent organs or give distant metastases. Pathologicalexamination and genetic features are crucial to establish diag-
nosis, whereas clinical presentation and imaging patterns are
often aspeciﬁc and misleading. To date, only few reports have
focused on mediastinal synovial sarcoma imaging ﬁndings.
Herein, we report a case of 13 cm primary mediastinal giant
synovial sarcoma, diagnosed in a 56-year-old patient admitted
in our Department of Radiology.2. Case report
A 56-year-old male presented to our hospital with a six-month
history of dyspnea and back pain, without coughing or
shortness of breath. Physical examination revealed nothing
of signiﬁcance in the chest and abdominal regions, as well as
in the extremities. During a routine workup, chest X-ray in
double projection (posterior–anterior and left lateral) revealeded.
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mediastinal enlargement (Fig. 1). The location of this mass was
the middle to posterior mediastinum using a classiﬁcation by
Felson. Then, the patient underwent a whole body multi-detec-
tor computed tomography (MDCT, Brilliance CT 16-slice Phi-
lips Medical systems, Best, The Netherlands) with i.v. contrast
medium, which deﬁned the presence of a 13 cm enhanced mass
in the upper-right region of the chest. The lesion appeared as
ﬁrmly adherent to the lateral mediastinal pleural surface, to
the posterior wall of trachea and to the lateral wall of esopha-
gus, and no cleavage was found between the mass and the car-
ina or the right bronchus. Moreover, no sign of pleural
effusion or lymphadenopathy was found (Fig. 2a–d). Follow-
ing, a ﬂexible bronchoscopy was performed, showing an
extrinsic compression of the right upper lobe bronchus but
the broncho-alveolar lavage (BAL) was negative for malignant
cells. Then, the patient underwent thoracotomy, which
revealed a large lesion arising from the right costo-vertebral
space, not belonging to the lung but adherent to the mediasti-Fig. 1 Chest X-ray. Posterior–anterior and left lateral chest radiogra
space-occupying lesion in the right hemithorax (a, b).
Fig. 2 MDCT. MDCT of the thorax (a, c lung window; b, d media
presence of a 13 cm round enhanced lesion in the posterior mediastinum
surface, to the posterior wall of trachea and to the lateral wall of esophnal pleura. The histopathological analysis of the excised mass
revealed poorly differentiated spindle-like tumor cells arranged
in bundles. Despite the lesion had been conﬁrmed as a malig-
nant mesenchymal tumor at pathology, the exact subtype was
hard to deﬁne. Immunohistochemistry showed strong positive
staining for vimentin, cytokeratin 8, cytokeratin 19 and focally
positive for cytokeratin 7 and EMA, and negative for CD34,
C5/6, calretine and primary pulmonary tumor marker (TTF-
1), which combined with the morphological proﬁle conﬁrmed
the diagnosis of mediastinal poorly differentiated monophasic
synovial sarcoma. The patient is still alive, disease-free, in
good health, currently undergoing follow-up.
3. Discussion
Synovial sarcoma has been deﬁned by the World Health Orga-
nization (WHO) in 2002 as a type of mesenchymal tissue cell
tumor that exhibits epithelial differentiation (2) and represents
the third most common soft-tissue sarcoma in adults,phs show a large right mediastinal enlargement caused by a round
stinum window; a, b axial images; c, d coronal MPR) shows the
. The lesion was found to be ﬁrmly adherent to the lateral pleural
agus. No sign of pleural effusion, or lymphadenopathy was found.
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Men and women are affected equally and the mean age at pre-
sentation is 32 years (4). Indeed, this sarcoma is prevalent in
adolescents and young adults between 15 and 40 years (5),
accounting for less than 2% of all soft tissue sarcomas in
patients older than 50 years. Although 85% of synovial sarco-
mas arises in joint cavities of lower limbs, rare cases may orig-
inate elsewhere, including mediastinum (5). Overall, primary
mediastinal synovial sarcoma is exceedingly rare. Indeed, in
a retrospective study by Bart et al. (6), only 1.4% of the total
3149 soft tissue sarcomas examined were primary mediastinal
sarcomas. Among these, synovial sarcoma accounted for only
2%. Despite its rarity, this tumor shows more aggressive clin-
ical behavior than other soft tissue synovial sarcomas. With
regard to clinical presentation, primary mediastinal synovial
sarcoma often reveals various and aspeciﬁc initial symptoms
due to compression, such as chest pain, cough, fever, back
pain, shortness of breath and dyspnea, which are common
ﬁndings in many mediastinal tumors. Therefore, it is crucial
to combine imaging and pathology to establish the diagnosis.
In particular, this neoplasm is characterized by the chromo-
somal translocation t(x;18)(p11;q110) and is thought to be of
totipotential mesenchymal cell origin (7). According to the var-
ious histological patterns of epithelial and spindle cells in the
mass, synovial sarcoma is divided into four subtypes (8): (1)
monophasic ﬁbrous synovial sarcoma, composed of homoge-
neous spindle cells with pale-staining nuclei arranged in fasci-
cles and sheets, embedded in a variable background of myxoid
to densely collagenous elements; (2) monophasic epithelial
synovial sarcoma, composed of relatively uniform spindle cells
with elongated nuclei, slightly basophilic cytoplasm and indis-
tinct cell borders with tumor cells densely packed and little
intervening stroma; (3) biphasic synovial sarcoma, composed
of both spindle and epithelial cells; (4) poorly differentiated
form. Calciﬁcation is a common ﬁnding in synovial sarcomas
at para-articular sites and can be found in 30% of lesions
(1), while has never been described in patients with thoracic
lesions (9). Moreover, genetic and immunochemistry examina-
tions play a pivotal role in the differential diagnosis of the
monophasic form from other stromal tumors, such as ﬁbrosar-
coma, hemangiopericytoma, leiomyosarcoma, and the spindle
cell variant of squamous cell carcinoma (10–12). Indeed, syno-
vial sarcoma can express mesenchymal markers such as vimen-
tin and the epithelial markers cytokeratin (type AE1/AE3),
bcl-2 and/or epithelial membrane antigen (EMA), in combina-
tion with CD34 negativity (13,14). In our case, the lesion wasFig. 3 Histopathology. Histopathological analysis showing: (a) tumo
Eosin staining (200·) showing poorly differentiated spindle-like tumorconﬁrmed as a malignant mesenchymal tumor at histopathol-
ogical analysis, but its subtype was hard to individuate. The
tumor cells were found to be positive for vimentin, cytokeratin
8, cytokeratin 19 and focally positive for cytokeratin 7 and
EMA, and negative for CD34, which, combined with the mor-
phological proﬁle, conﬁrmed the diagnosis of mediastinal
monophasic synovial sarcoma (Fig. 3a,b). Nevertheless, in-situ
ﬂuorescence hybridization showed in our patient the chromo-
somal translocation t(x;18)(p11;q110) involving the SYT gene
on the long arm of chromosome 18 and the SSX1 or SSX2
gene on the short arm of the X chromosome, which has been
demonstrated in more than 90% of synovial sarcomas, regard-
less of histological subtypes (15). Since this genetic alteration is
not associated with other sarcomas, it may be considered as a
speciﬁc biomarker for diagnosing synovial sarcomas (7). With
regard to imaging tools, chest X-ray is usually the ﬁrst and less
accurate exam performed in all thoracic pathologies.
Contrary, Multi-Detector Computed Tomography (MDCT)
may reveal space-occupying lesions in the mediastinum with
no speciﬁc radiological pattern to other mediastinal stromal
tumors, including necrotic, hemorrhagic or cystic components
on section. In particular, on chest radiographs, mediastinal
synovial sarcomas may be depicted as a pulmonary parenchy-
mal consolidation or mass (with sharp and ill-deﬁned mar-
gins), a pleural-based mass, a focal pleural thickening with
or without a central mass or near-complete opaciﬁcation of
the hemithorax (15). There is no propensity for sidedness
(15). An ipsilateral pleural effusion may be evident, such as
pneumothorax. Anyway, MDCT is much more sensitive in
detecting calciﬁed tumor matrix. On MDCT, mediastinal
synovial sarcoma typically appears as a well-deﬁned, heteroge-
neously enhanced mass that contains areas of ﬂuid attenua-
tion compatible with necrosis or hemorrhage (15–17).
Likewise in our patient, the reported radiodensity values are
20–40 HU on unenhanced MDCT (9). Mediastinal lymph
node enlargement is uncommon (15). The real site of origin
(lung, pleura or mediastinum) is often unclear, but acute or
recurrent hemothorax and a rim of ground-glass opacity sur-
rounding the mass has been reported in case of pulmonary
synovial sarcoma. On Magnetic Resonance Imaging (MRI),
compared with soft-tissue sarcoma, mediastinal synovial sar-
coma shows less vascularity and a ‘‘triple sign’’ pattern on
T2-weighted images, consisting of bright, dark and gray areas,
representing the tumor, hemorrhage, and necrosis, respectively
(18). Unfortunately, our patient could not undergo MRI
because of claustrophobia.r cells are found to be positive for cytokeratin 8; (b) Ematossilina–
cells arranged in bundles.
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with a high recurrence rate and ability to progress to meta-
static stage. These neoplasms may invade adjacent organs or
metastatize via the blood, rarely via the lymphatic system.
No sign of distant metastasis or lymph node enlargement
became evident during the 2-year follow up in our patient.
Despite the optimal treatment strategy is still unclear due to
lack of data of this rare disease, surgery is the treatment of
choice in resectable patients (19). For tumors that can be com-
pletely excised, surgical resection with or without radiotherapy
has been found effective in establishing local control. Patient
age, involvement of surgical margins, and tumor size guides
the decision about whether additional adjuvant chemotherapy
and/or radiotherapy is needed. Certainly, tumor response has
occurred with ﬁrst-line chemotherapy regimens consisting of
ifosfamide-based chemotherapy (with or without doxorubi-
cin), however, whether there is a substantial effect on long-
term survival is uncertain, and toxicity and side effects must
be weighed against potential beneﬁts. Prognosis reported in
the poor differentiated forms is poor, but with aggressive mul-
timodal therapy, moderate to high survival has been reported
(20). Anyway, any adjuvant chemo- or radiotherapy was
denied by our patient. The overall 5-year survival rate is
50%, and poor prognostic risk factors include age older than
20 years, female sex, incomplete resection, tumor size >5 cm,
extensive tumor necrosis, high number of mitoses (>10 per
10 high-power ﬁelds), neurovascular invasion (21). With the
exception of the gender, our patient presented all these poor
prognostic risk factors, especially the tumor diameter longer
than 13 cm. Also early relapse (<18 months) has been
reported to be signiﬁcantly associated with worse prognosis,
but no relapse has occurred in our patient during the 2-year
follow up.
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